Carry-over in pre-dose samples for steady state BE [Study As­sess­ment]

posted by hirenpharm – Ahmedabad, 2019-03-29 20:56  – Posting: # 20103
Views: 1,406

Hello everyone,

We did a multiple dose (5 weeks, 1 TDS patch every week) bioequivalence study. The BE was assessed at week 5 at steady state. It was a 3-period study. In period 2 and 3, we observed some carry-over from the previous period treatments. I remember, the 5% of Cmax rule for single-dose studies. But, can someone please throw some light on how to handle this carry-over in multiple dose steady state studies? Does the carry-over in week 1 pre-dose really impact week 5 steady state parameters? any regulatory guidance/published articles will be really helpful.


Edit: Category changed; see also this post #1[Helmut]

Dr. Hiren Mehta

Complete thread:

Activity
 Admin contact
20,103 posts in 4,243 threads, 1,383 registered users;
online 12 (2 registered, 10 guests [including 7 identified bots]).
Forum time (Europe/Vienna): 10:05 CET

We must be careful not to confuse data with the abstractions
we use to analyze them.    William James

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5